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ABSTRACT
Controlling for confounding bias is crucial in causal inference. Distinct methods are currently employed to mitigate the effects of
confounding bias. Each requires the introduction of a set of covariates, which remains difficult to choose, especially regarding
the different methods. We conduct a simulation study to compare the relative performance results obtained by using four
different sets of covariates (those causing the outcome, those causing the treatment allocation, those causing both the outcome
and the treatment allocation, and all the covariates) and four methods: g-computation, inverse probability of treatment weighting,
full matching and targeted maximum likelihood estimator. Our simulations are in the context of a binary treatment, a binary
outcome and baseline confounders. The simulations suggest that considering all the covariates causing the outcome led to
the lowest bias and variance, particularly for g-computation. The consideration of all the covariates did not decrease the bias
but significantly reduced the power. We apply these methods to two real-world examples that have clinical relevance, thereby
illustrating the real-world importance of using these methods. We propose an R package RISCA to encourage the use of
g-computation in causal inference.
Introduction
The randomised controlled trial (RCT) remains the primary design for evaluating the marginal (population average) causal
effect of a treatment, i.e., the average treatment effect between two hypothetical worlds where: i) everyone is treated and ii)
everyone is untreated1. Indeed, a well-designed RCT with a sufficient sample size ensures the baseline comparability between
groups, thus allowing the estimation of a marginal causal effect. Nevertheless, it is well established that RCT is performed
under optimal circumstances (e.g., over-representation of treatment-adherent patients, low frequency of morbidity), which may
be different from real-life practices2. Observational studies have the advantage of limiting the issue of external validity, but
treated and untreated patients are often non-comparable, leading to a high risk of confounding bias.
To reduce such confounding bias, the vast majority of observational studies have been based on multivariable models
(mainly linear, logistic, or Cox models), allowing for the direct estimation of conditional (subject-specific) effects, i.e., the
average effect across sub-populations of subjects who share the same characteristics. Several methods have been proposed to
estimate marginal causal effects in observational studies, amongst which propensity score (PS)-based methods are increasingly
used in epidemiology and medical research3.
Propensity score-based methods make use of the PS in four different ways to account for confounding, namely matching,
stratification, conditional adjustment4 and inverse probability of treatment weighting (IPTW)5. Stratification and conditional
adjustment on PS are associated with the highest bias6–8, because the two methods estimate the conditional treatment effect
rather than the marginal causal effect. Matching on PS remains the most common approach with a usage rate of 83.8% in
303 surgical studies using PS-based methods9 and 68.9% in 296 medical studies (without restriction regarding the field) also
using PS-methods10. The IPTW appears to be less biased and associated with a lower variance than matching in several
studies8, 11–14. Nevertheless, in particular settings, full matching (FM) was associated with lower mean square error (MSE) in
other studies15–17.
Multivariable models, even non-linear ones, can also be used to indirectly estimate the marginal causal effect with g-
computation (GC)18. This method is also called the parametric g-formula1 or (g-)standardisation19 in the literature. Snowden et
al.20 and Wang et al.21 detailed the corresponding methodology for estimating the average treatment (i.e., marginal causal)
effect on the entire population (ATE) or only on the treated (ATT), respectively. The ATE is the average effect, at the population
level, of moving an entire population from untreated to treated. The ATT is the average effect of treatment on those subjects
who ultimately received the treatment22. Furthermore, some authors23, 24 have proposed combinations of GC and PS to improve
the estimation of the marginal causal effect. These methods are known as doubly robust estimators (DRE) because they require
the specification of both the outcome (for GC) and treatment allocation (for PS) mechanisms to minimise the impact of model
misspecification. Indeed, these estimators are consistent as long as either the outcome model or the treatment model is estimated
correctly25.
Each of these methods carries out the adjustment in different ways, but all of these methods rely on the same condition: a
correct specification of the PS or the outcome model1. In practice, a common issue is choosing the set of covariates to include
to obtain the best performance in terms of bias and precision. Three simulation studies7, 26, 27 have investigated this issue for
PS-based methods. They studied four sets of covariates: those causing the outcome, those causing the treatment allocation,
those are a common cause of both the treatment allocation and the outcome, and all the covariates. For the rest of this paper, we
called these strategies the outcome set, the treatment set, the common set and the entire set, respectively. These studies argued in
favour of the outcome or common sets for PS-based methods, but it is not immediately clear that such works will generalise to
other methods of causal inference. Brookhart et al.26 and Lefebvre et al.27 focused on count and continuous outcomes. Austin
et al.7 investigated binary outcomes on matching, stratification and adjustment on PS. However, GC and DRE also require
the correct specification of the outcome model with a potentially different set of covariates. Recent works have shown that
efficiency losses can accompany the inclusion of unnecessary covariates28–31. De Luna et al.32 also highlighted the variance
inflation caused by the treatment set. In contrast, VanderWeele and Shpitser33 suggested the inclusion of both the outcome and
the treatment sets.
Before selecting the set of covariates, one needs to select the method to employ. Several studies have compared the
performances of GC, PS-based methods and DRE in a point treatment study to estimate the ATE13, 23, 25, 34–36. Half of these
studies investigated a binary outcome13, 25, 34. Only Colson et al.17 studied the ATT, but they focused on a continuous outcome.
Except in Neugebauer and van der Laan25, these studies only investigated the ATE (or ATT) defined as a risk difference. The
CONSORT recommended the presentation of both the absolute and the relative effect sizes for a binary outcome, "as neither
the relative measure nor the absolute measure alone gives a complete picture of the effect and its implications"37. None of
these studies was interested in the set of covariates necessary to obtain the best performance.
In our study, we sought to compare different sets of covariates to consider to estimate a marginal causal effect. Moreover,
we compared GC, PS-based methods and DRE for both the ATE and ATT, either in terms of risk difference or marginal causal
OR. Three main types of outcome are used in epidemiology and medical research: continuous, binary and time-to-event
outcomes. We focused on a binary outcome because i) a continuous outcome is often appealing for linear regression where the
two conditional and marginal causal effects are collapsible38, and ii) time-to-event analyses present additional methodological
difficulties, such as the time-dependant covariate distribution39. We also limit our study to a binary treatment, as in the current
literature, and the extension to three or more modalities is beyond the scope of our study.
The paper is structured as follows. In the next section, the methods are detailed. The third section presents the design and
results of the simulations. In the fourth section, we consider two real data sets. Finally, we discuss our results in the last section.
Methods
Setting and notations
Let A denote the binary treatment of interest (A = 1 for treated patients and 0 otherwise), Y denote the binary outcome
(Y = 1 for events and 0 otherwise), and L denote a set of baseline covariates. Consider a sample of size n in which one
can observe the realisations of these random variables: a, y, and l, respectively. Define pia = E(P(Y = 1|do(A = a),L)) or
pia = E(P(Y = 1|do(A = a),L)|A = 1) as the expected proportions of event if the entire (ATE) or the treated (ATT) populations
were treated (do(A= 1)) or untreated (do(A= 0)), respectively40. From these probabilities, the risk difference can be estimated
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as ∆pi = pi1−pi0 and the log of the marginal causal OR estimated as θ = logit(pi1)/logit(pi0), where logit(•) = log(•/(1−•)).
The methods described bellow allow for the estimation of both the ATE and the ATT effects.
Causal inference requires the three following assumptions, called identifiability conditions: i) The values of exposure under
comparisons correspond to well-defined interventions that, in turn, correspond to the versions of treatment in the data. ii) The
conditional probability of receiving every value of treatment, though not decided by the investigators, depends only on the
measured covariates. iii) The conditional probability of receiving every value of the treatment is greater than zero, i.e., is
positive. These assumptions are known as consistency, (conditional) exchangeability and positivity, respectively1. However,
PS-based methods rely on treatment allocation modelling to obtain a pseudo-population in which the confounders are balanced
across treatment groups. Covariate balance can be checked by computing the standardised difference of the covariates included
in the PS between the two treatment groups10. In contrast, GC relies on outcome modelling to predict hypothetical outcomes for
each subject under each treatment regimen. Note that one can ignore the lack of positivity if one is willing to rely on Q-model
extrapolation1. As is the case for standard regression models, these methods also require the assumptions of no interference, no
measurement error and no model misspecification.
Weighting on the inverse of the propensity score
Formally, the PS is pi = P(Ai = 1|Li), i.e. the probability that subject i (i = 1, ...,n) will be treated according to his or
her characteristics Li at the time of the treatment allocation4. It is often estimated using a logistic regression. The IPTW
makes it possible to reduce confounding by correcting the contribution of each subject i by a weight ωi. For ATE, Xu et
al.41 defined ωi = AiP(Ai = 1)/pi +(1−Ai)P(Ai = 0)/(1− pi). The use of stabilised weights has been shown to produce
a suitable estimate of the variance even when there are subjects with extremely large weights5, 41. For ATT, Morgan and
Todd42 defined ωi = Ai+(1−Ai)pi/(1− pi). Based on ωi, the following weighted univariate logistic regression can be fitted:
logit{P(Y = 1|A)} = αˆ0 + αˆ1A, resulting in pˆi0 = (1+ exp(−αˆ0))−1, pˆi1 = (1+ exp(−αˆ0− αˆ1))−1, and θˆ = αˆ1. To obtain
v̂ar(θˆ), we used a robust sandwich-type variance estimator5 with the R package sandwich43.
Full Matching on the propensity score
The FM minimises the average within-stratum differences in the PS between treated and untreated subjects16. Then, two
weighting systems can be applied in each stratum, making it possible to estimate either the ATE or the ATT unlike other matching
methods which can only estimate the ATT44. If t and u denote the number of treated and untreated subjects in a given stratum, one
can define the weight for a subject i in this stratum as ωi = AiP(A = 1)(t+u)/u+(1−Ai)(1−P(A = 1))(t+u)/t for ATE and
ωi =Ai+(1−Ai)t/u for ATT16. In the latter case, the weights of untreated subjects are rescaled such that the sum of the untreated
weights across all the matched sets is equal to the number of untreated subjects: ω˜i = ωi×∑nj=1(1−A j)/∑nj=1ω j(1−A j)45.
From the resulting paired data set, we fitted a weighted univariate logistic regression, and the rest of the data analysis is
tantamount to IPTW. We used the R package MatchIt45 to generate the pairs.
G-computation
Consider the following multivariable logistic regression logit{P(Y = 1|A,L)}= γA+βL. This regression is frequently called
the Q-model20. Once fitted, one can compute for all subjects Pˆ(Yi = 1|do(Ai = 1),Li) and Pˆ(Yi = 1|do(Ai = 0),Li), i.e. the two
expected probabilities of events if they were treated or untreated20. For ATE, one can then obtain pˆia = n−1∑i Pˆ(Yi = 1|do(Ai =
a),Li). The same procedure can be performed amongst the treated patients for ATT21. For implementation in practice, consider
a treated subject (Ai = 1) included in the fit of the Q-model. Thanks to this model, one can then compute for this subject his
or her predicted probabilities of the event if he or she received the treatment (do(Ai = 1)) or not (do(Ai = 0)). Computing
these predicted probabilities for all the subjects, one can obtain two vectors of probabilities if the entire sample were treated or
not. The corresponding means correspond to pˆi1 and pˆi0, respectively. We obtained v̂ar(θˆ) by simulating the parameters of the
multivariable logistic regression assuming a multinormal distribution46. Note that we could have used bootstrap resampling
instead. However, regarding the computational burden of bootstrapping and the similar results obtained by Aalen et al.46, the
variance estimates in the simulation study were only based on parametric simulations. We used both bootstrap resampling and
parametric simulations in the applications.
Targeted Maximum Likelihood Estimator
Amongst the several existing DREs, we focused on the targeted maximum likelihood estimator (TMLE)24, for which estimators
of ATE and ATT have been proposed47. The TMLE begins by fitting the Q-model to estimate the two expected hypothetical
probabilities of events pˆi1 and pˆi0. An additional "targeting" step involves estimation of the treatment allocation mechanism, i.e.
the PS P(Ai = 1|Li), which is then used to update the initial estimates obtained by GC. In the presence of residual confounding,
the PS provides additional information to improve the initial estimates. Finally, the updated estimates of pˆi1 and pˆi0 are used to
generate ∆̂pi or θˆ . We used the efficient influence curve to obtain standard errors47, 48. A recent tutorial provides a step-by-step
guided implementation of TMLE49.
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Simulation study
Design
We used a close data generating procedure from previous studies on PS models7, 50. We generated the data in three steps.
i) Nine covariates (L1, ..., L9) were independently simulated from a Bernoulli distribution with a parameter equal to 0.5
for all covariates. ii) We generated the treatment A according to a Bernoulli distribution with a probability obtained by
the logistic model with the following linear predictor: γ0 + γ1L1 + ...+ γ9L9. We fixed the parameter γ0 at -3.3 or -5.2 to
obtain a percentage of treated patients equal to 50% for scenarios related to ATE and 20% for ATT, respectively. iii) We
simulated the event Y using a Bernoulli distribution with a probability obtained by the logistic model with the following
linear predictor: β0+β1A+β2L1+ ...+β10L9. We set the parameter β1 for a conditional OR at 0 (the null hypothesis is no
treatment effect) or 2 (the alternative hypothesis is a negative impact of treatment). We also fixed the parameter β0 at -3.65
and -3.5 to obtain a percentage of the event close to 50% in ATE and ATT, respectively. Figure 1 presents the values of the
regression coefficients γ1 to γ9 and β1 to β10. We considered four covariates sets as explained in the introduction: the outcome
set included the covariates L1 to L6, the treatment set included the covariates L1,L2,L4,L5,L7,L8, the common set included
the covariates L1,L2,L4,L5, and the entire set included the covariates L1 to L9. For each of the four methods and the four
covariate sets, we studied the performance under different sample sizes: n =100, 300, 500 and 2000. For each scenario, we
randomly generated 10 000 data sets. We computed the theoretical values of pi1 and pi0 by averaging the values of pi1 and pi0
obtained from univariate logistic models (treatment as the only covariate) fitted from data sets simulated as above, except that
the treatment A was simulated independently of the covariates L50. We reported the following criteria: i) the percentage of
non-convergence, ii) the mean absolute bias (e.g., E(θˆ)−θ ), iii) the MSE (E[(θˆ −θ)2]), the variance estimation bias (VEB =
100× (
√
E[V̂ ar(θˆ)]/
√
Var(θˆ)−1))51, the empirical coverage rate of the nominal 95% confidence intervals (CIs), defined as
the percentage of 95% CI including the theoretical value, the type I error, defined as the percentage of rejection of the null
hypothesis under the null hypothesis, and the statistical power, defined as the percentage of rejections of the null hypothesis
under the alternative hypothesis. The MSE was our primary performance measure of interest because it combines bias and
variance. We assumed that the identifiability conditions hold in these scenarios. We further performed the same simulations by
omitting L1 in the PS or in the Q-model to evaluate the impact of an unmeasured confounder. We performed all the analyses
using R version 3.6.052.
Results
Convergence
Non-convergence only occurred for ATT estimation when sample sizes were lower or equal to 300 subjects (see Figure 2). The
GC, IPTW and FM had a minimal convergence percentage higher than 98%, even under small sample size (n=100). Similarly,
TMLE experienced some difficulty in converging for ATT estimation in the medium-sized sample (n=300). However, they
experienced severe difficulty in converging in the small sample with a convergence percentage of approximately 92%.
Mean bias
As expected with the common set, the mean absolute bias of θ was close to zero for GC, IPTW and TMLE when the three
identifiability assumptions hold with a maximum at -0.028 given moderate sample size (n=300) under the alternative hypothesis
for ATT estimation (Table 1). Note that the three other covariate sets led to a bias close to zero with a maximum of 0.053
for TMLE with the entire set given small sample size (n=100) under the alternative hypothesis for ATE estimation (Table 2).
Furthermore, FM was also associated with a similar bias with a maximum of 0.082 given a small sample size (n=100), with the
treatment set under the alternative hypothesis for the ATE estimation. With an unmeasured confounder, the bias increased in all
scenarios with a minimum of 0.456 for GC with the common set given a large sample size for the ATT estimation (see Online
Supporting Information (OSI) for complete results). The results were similar under the null hypothesis (see OSI).
Variance
For all methods, the outcome set led to the lowest MSE, followed closely by the common set. G-computation led to the lowest
MSE and FM to the highest. In ATT, IPTW had lower MSE than TMLE. Note that the VEB was particularly high for FM in all
ATE scenarios with a minimum of -17.5% (n=500 with the outcome set). For the ATT, FM also had a higher VEB than other
methods, apart from TMLE with the treatment or entire sets in sample sizes of fewer than 2000 subjects. In the presence of an
unmeasured confounder, the MSE increased in all scenarios in agreement with the increase in bias. The VEBs did not change
notably with an unmeasured confounder.
Coverage and error rates
G-computation produced coverage rates close to 95%, except for ATE in a small sample size leading to an anti-conservative
95% CIs with a minimum of 91.7% with the entire set under the null hypothesis. Anti-conservatives 95% CIs were also
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produced by FM in all scenarios, and by TMLE given a small sample size. Conversely, conservative 95% CIs were obtained
when using TMLE for the ATT with the entire or the treatment sets, and when using IPTW for ATT or ATE with the outcome
or the common sets.
Lending confidence to these results, the type I error was close to 5% for GC in all scenarios and may vary for other methods.
The power was more impacted by the choice of the covariate set. The outcome set led to the highest power for GC.
Applications
We illustrated our findings by using two real data sets. First, we compared the efficiency of two treatments, i.e., Natalizumab
and Fingolimod, sharing the same indication for active relapsing-remitting multiple sclerosis. Physicians preferentially use
Natalizumab in practice for more active disease, indicating possible confounders. Given the absence of a clinical trial with a
direct comparison of their efficacy, Barbin et al.53 recently conducted an observational study. We reused their data. Second, we
sought to study barbiturates that can lead to a reduction of the patient functional status. Indeed, barbiturates are suggested in
Intensive Care Units (ICU) for the treatment of refractory intracranial pressure increases. However, the use of barbiturates is
associated with haemodynamic repercussions that can lead to brain ischaemia and immunodeficiency, which may contribute
to the occurrence of infection. These applications were conducted in accordance with the French law relative to clinical
noninterventional research. According to the French law on Bioethics (July 29, 1994; August 6, 2004; and July 7, 2011, Public
Health Code), the patients’ written informed consent was collected. Moreover, data confidentiality was ensured in accordance
with the recommendations of the French commission for data protection (Commission Nationale Informatique et Liberté, CNIL
decisions DR-2014-558 and DR-2013-047 for the first and the second application, respectively).
To define the four sets of covariates, we asked experts (D.L. for multiple sclerosis and M.L. for ICU) which covariates were
causes of the treatment allocation and which were causes of the outcome, as proposed by VanderWeele and Shpitser33. We
checked the positivity assumption and the covariate balance (see OSI). We applied B-spline transformations for continuous
variables when the log-linearity assumption did not hold.
Natalizumab versus Fingolimod to prevent relapse in multiple sclerosis patients
The outcome was at least one relapse within one year of treatment initiation. Six hundred and twenty-nine patients from the
French national cohort OFSEP were included (www.ofsep.org). The first part of Table 3 presents a description of their baseline
characteristics.
All included patients could have received either treatment. Therefore, we sought to estimate the ATE. The first part of
Table 4 presents the results according to the different possible methods and covariate sets. The GC, IPTW and TMLE yield
similar results regardless of the covariate sets considered. Thus, Fingolimod exhibits lower efficacy than Natalizumab with an
OR [95% CI] ranging from 1.50 [1.02; 2.21] for IPTW with the entire set to 1.55 [1.06; 2.28] for GC with the common set.
When using FM, the OR ranged from 1.73 [1.19; 2.51] with the outcome set to 1.78 [1.23; 2.56] with the common set. Note
that, unlike IPTW, FM does not to balance all covariates in the outcome set with standardised differences higher than 10%.
Overall, the confounder-adjusted proportion of patients with at least one relapse within the first year of treatment was lower
in the hypothetical world where all patients received Natalizumab (approximately 20% and varying slightly depending on
method and set of covariates) than one in which all patients received Fingolimod (approximately 28%). This difference of
approximately 8% is clinically meaningful and suggests the superiority of Natalizumab over Fingolimod to prevent relapses at
one year. This result was concordant with the recent clinical literature53, 54.
Impact of barbiturates in the ICU on the functional status at three months
We define an unfavourable functional outcome by a 3-month Glasgow Outcome Scale (GOS) lower than or equal to 3. We
used the data from the French observational cohort AtlanREA (www.atlanrea.org) to estimate the ATT of barbiturates because
physicians recommended these drugs to a minority of severe patients. The second part of Table 3 presents the baseline
characteristics of the 252 included patients.
The second part of Table 4 presents the results according to the different possible methods and covariate sets. G-computation
and TMLE lead to the conclusion of a significant negative effect of barbiturates regardless of the covariate set considered with
an OR [95% CI] ranging from 0.43 [0.25; 0.76] for GC with the common set to 0.51 [0.29; 0.90] for TMLE with the entire set.
By contrast, the results were discordant when using different covariate sets for IPTW and FM. We report, for instance, OR
estimates obtained by FM ranging from 1.520 with the outcome set to 2.300 with the common set. In line with the simulation
study, the estimated standard errors were higher for these methods (0.294 and 0.293 for GC and TMLE when the outcome set
was considered, respectively) leading to lower power. Note also that standardised differences were higher than 10% for the
IPTW with the entire set (see OSI) and for FM with the outcome, the treatment and the entire sets.
Depending on the methods and sets of covariates included, we estimated that from 18% to 20% of patients treated with
barbiturates had an unfavourable GOS at three months. If these patients had not received barbiturates, the methods estimate
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that from 30% to 35% would have had an unfavourable GOS at three months. For the patients, this difference is meaningful
but full clinical relevance depends also on the effect of barbiturates on other clinically relevant outcomes, such as death or
ventilator-associated pneumonia. However, the results obtained by GC or TMLE differ with those obtained by Majdan et al.55,
who did not find any significant effect of barbiturates on the GOS at six months. Two main methodological reasons can explain
this difference: the GOS was at six months rather than three months post-initiation, and the authors used multivariate logistic
regression leading to a different estimand.
Discussion
The aim of this study was to better understand the different sets of covariates to consider when estimating the marginal causal
effect.
The results of our simulation study, limited to the studied scenarios, highlight that the use of the outcome set was associated
with the lower bias and variance, principally when associated with GC, for both ATE and ATT. As expected, an unmeasured
confounder led to increased bias, regardless of method employed. Although we do not report an impact on the variance, the
effect’s over- or under-estimation leads to the corresponding over- or under-estimation of power and compromises the validity
of the causal inference.
The performance of FM is lower than that of the other studied methods, especially for the variance. Our results were in
line with King and Nielsen56, who argued for halting the use of PS matching for many reasons such as covariate imbalance,
inefficiency, model dependence and bias. Nonetheless, Colson et al.17 found slightly higher MSE for GC than FM. Their more
simplistic scenario, with only two simulated confounders leading to little covariate imbalance, could explain the difference with
our results. Moreover, is unclear whether they accounted for the matched nature of the data, as recommended by Austin and
Stuart16 or Gayat et al.50.
While DRE offers protection against model misspecification23, 34, 36, our simulation study resulted in the finding that GC was
more robust to the choice of the covariate set than the other methods, TMLE included. This result was particularly important
when the treatment set was taken into account, which fits with the results of Kang and Schafer35: when both the PS and the
Q-model were misspecified, DRE had lower performance than GC. Furthermore, GC was associated with lower variance than
DRE in several simulation studies13, 17, 35, which accords with our results.
The first application to multiple sclerosis (ATE) illustrated similar results between the studied methods. In contrast, the
second application (ATT) to severe trauma or brain-damaged patients showed different results between the methods. In
agreement with simulations, the estimations obtained with GC or TMLE were similar in terms of logOR estimation and variance
regardless of the covariate set considered. Estimations obtained with IPTW or FM were highly variable, depending on the
covariate set employed: some indicated a negative impact of barbiturates and others did not. These results also tended to
demonstrate that GC or TMLE had the highest statistical power. Variances obtained by parametric simulations or by bootstrap
resampling were similar (results not displayed).
One can, therefore, question the relative predominance of the PS-based approach compared to GC, although there are
several potential explanations. First, there appears to be a pre-conceived notion according to which multivariable non-linear
regression cannot be used to estimate marginal absolute and relative effects57. Indeed, under logistic regression, the mean
sample probability of an event is different from the event probability of a subject with the mean sample characteristics. Second,
while there is an explicit variance formula for the IPTW58, the equivalent is missing for the GC. The variance must be obtained
by bootstrapping, simulation or the delta method. Third, several didactic tutorials on PS-based methods can be found, for
instance59–61.
We still believe that PS-based methods may have value when multivariate modelling is complex, for instance, for multi-state
models62. In future research, it would be interesting to examine whether the use of potentially better settings would provide
equivalent results, such as the Williamson estimator for IPTW58, the Abadie-Imbens estimator for PS matching63, or bounded
the estimation of TMLE, which can also be updated several times36. We also emphasise that we did not investigate these
methods when the positivity assumption does not hold. Several authors have studied this problem13, 25, 35, 36, 64. G-computation
was less biased than IPTW or DRE except in Porter et al.36, where the violation of the positivity assumption was also associated
with model misspecifications. The robustness of GC to non-positivity could be due to a correct extrapolation into the missing
sub-population, which is not feasible with PS1. Other perspectives of this work are to extend the problem to i) time-to-event,
continuous or multinomial outcomes and ii) multinomial treatment. However, implementing GC using continuous treatment
raises many important considerations concerning the research question and resulting inference64.
To facilitate its use in practice, we have implemented the estimation of both ATE and ATT, and their 95% CI, from a logistic
model in the existing R package entitled RISCA (available at cran.r-project.org/web/packages/RISCA). We provide an example
of R code in the appendix. Note that the package did not consider the inflation of the type I error rate due to the modelling steps
of the Q-model. Users also have to consider novel strategies for post-model selection inference.
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In the applications, we classified covariates into sets based on experts knowledge33. However, several statistical methods
can be useful when no clinical knowledge is available. Heinze et al.65 proposed a review of the most used, while Witte and
Didelez66 reviewed strategies specific to causal inference. Alternatively, data-adaptive methods have recently been developed,
such as the outcome-adaptive LASSO67 to select covariates associated with both the outcome and the treatment allocation.
Nevertheless, according to our results, it may be preferable to focus on constructing the best outcome model based on the
outcome set. For instance, the consideration of a super learner68, 69, merging models and modelling machine learning algorithms
may represent an exciting perspective70.
Finally, we emphasise that the conclusions from our simulation study cannot be generalised to all situations. They are
consistent with the current literature on causal inference, but theoretical arguments are missing for generalisation. Notably, our
results must be considered in situations where both the PS and the Q-model are correctly specified and where positivity holds.
To conclude, we demonstrate in a simulation study that adjusting for all the covariates causing the outcome improves the
estimation of the marginal causal effect (ATE or ATT) of a binary treatment in a binary outcome. Considering only the covariates
that are a common cause of both the outcome and the treatment is possible when the number of potential confounders is large.
The strategy consisting of considering all available covariates, i.e., no selection, did not decrease the bias but significantly
decreased the power. Amongst the different studied methods, GC had the lowest bias and variance regardless of covariate set
considered. Consequently, we recommend that the use of the GC with the outcome set, because of its highest power in all the
simulated scenarios. For instance, at least 500 individuals were necessary to achieve a power higher than 80% in ATE, with a
theoretical OR at 2, and a percentage of treated subjects at 50%. In ATT, we needed larger sample size to reach a power of 80%
because the estimation considers only the treated patients. With 2000 individuals, all the studied methods with the outcome set
led to a bias close to zero and a statistical power superior to 95%.
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Figure 1. Causal diagram. Solid lines corresponded to a strong association (OR=6.0) and dashed lines to a moderate one
(OR=1.5).
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Figure 2. Percentage of simulation iterations which did not converge according to the methods.
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n method selection mean bias logORstrategy pi0 pi1 ∆pi logOR MSE MSE* VEB coverage power
100
GC
outcome 0.000 -0.001 -0.001 0.012 0.526 0.716 -6.2 94.1 17.7
treatment 0.002 -0.001 -0.003 0.006 0.580 0.786 -5.7 94.1 14.0
common 0.002 -0.001 -0.003 0.006 0.552 0.735 -4.2 94.8 15.1
entire -0.001 -0.001 -0.001 0.013 0.558 0.768 -8.8 93.3 16.9
IPTW
outcome 0.000 -0.001 -0.001 0.008 0.578 0.727 10.8 97.3 7.8
treatment -0.000 -0.001 -0.001 0.000 0.716 0.837 -1.2 95.1 9.8
common 0.002 -0.001 -0.003 0.003 0.587 0.743 6.6 96.8 8.8
entire -0.003 -0.001 0.002 0.005 0.741 0.838 -1.5 95.2 9.6
TMLE
outcome -0.001 -0.001 0.000 0.002 0.694 0.794 30.0 95.7 5.8
treatment 0.000 -0.001 -0.001 -0.020 0.876 0.955 183.3 98.8 1.0
common -0.000 -0.001 -0.001 -0.001 0.702 0.794 10.4 95.3 7.3
entire -0.003 -0.001 0.001 -0.013 0.886 0.953 412.2 98.8 0.5
FM
outcome -0.004 -0.001 0.003 0.022 0.665 0.787 -16.7 90.1 18.9
treatment -0.006 -0.001 0.004 0.017 0.822 0.911 -32.3 81.3 25.2
common -0.001 -0.001 -0.000 0.010 0.653 0.795 -15.3 91.0 17.5
entire -0.008 -0.001 0.006 0.022 0.842 0.921 -33.8 80.3 26.7
300
GC
outcome 0.001 -0.001 -0.002 -0.021 0.283 0.555 -1.6 94.5 43.6
treatment 0.002 -0.001 -0.003 -0.024 0.319 0.606 -2.3 94.3 35.2
common 0.002 -0.001 -0.003 -0.023 0.304 0.561 -1.5 94.8 38.5
entire 0.001 -0.001 -0.002 -0.022 0.297 0.600 -2.6 94.0 39.9
IPTW
outcome 0.002 -0.001 -0.003 -0.027 0.301 0.556 16.4 97.9 24.0
treatment 0.001 -0.001 -0.002 -0.026 0.372 0.628 6.6 96.2 21.4
common 0.003 -0.001 -0.004 -0.028 0.318 0.563 9.1 96.8 26.1
entire 0.001 -0.001 -0.002 -0.025 0.361 0.622 11.7 97.2 20.0
TMLE
outcome 0.000 -0.001 -0.001 -0.023 0.358 0.577 -2.3 93.6 29.0
treatment 0.002 -0.001 -0.003 -0.035 0.454 0.683 51.2 99.1 6.8
common 0.001 -0.001 -0.002 -0.023 0.378 0.582 -3.5 93.0 26.5
entire 0.002 -0.001 -0.003 -0.035 0.432 0.674 81.8 99.3 4.4
FM
outcome -0.000 -0.001 -0.001 -0.020 0.351 0.579 -11.7 91.9 37.2
treatment -0.001 -0.001 -0.000 -0.022 0.444 0.656 -30.2 82.7 38.9
common 0.001 -0.001 -0.002 -0.024 0.363 0.587 -14.6 90.4 36.9
entire -0.001 -0.001 0.000 -0.020 0.439 0.662 -29.3 83.2 39.1
500
GC
outcome 0.001 -0.001 -0.002 -0.014 0.217 0.509 -1.1 94.7 64.5
treatment 0.001 -0.001 -0.002 -0.014 0.245 0.556 -1.5 94.4 53.6
common 0.001 -0.001 -0.002 -0.015 0.233 0.618 -0.8 94.8 57.6
entire 0.001 -0.001 -0.002 -0.014 0.228 0.552 -2.0 94.2 60.5
IPTW
outcome 0.002 -0.001 -0.003 -0.019 0.230 0.509 16.5 97.9 43.3
treatment 0.000 -0.001 -0.001 -0.013 0.285 0.574 6.8 96.6 35.4
common 0.002 -0.001 -0.003 -0.018 0.244 0.514 9.2 96.8 43.7
entire 0.000 -0.001 -0.001 -0.014 0.274 0.571 12.3 97.2 33.9
TMLE
outcome 0.001 -0.001 -0.002 -0.015 0.272 0.521 -4.7 93.4 48.5
treatment 0.001 -0.001 -0.002 -0.018 0.347 0.618 35.0 99.1 15.9
common 0.000 -0.001 -0.001 -0.013 0.289 0.527 -4.8 93.1 43.7
entire 0.001 -0.001 -0.002 -0.019 0.328 0.611 51.1 99.3 12.9
FM
outcome 0.001 -0.001 -0.002 -0.015 0.265 0.525 -9.9 92.4 53.0
treatment -0.001 -0.001 -0.000 -0.011 0.346 0.597 -31.0 82.7 51.7
common 0.001 -0.001 -0.001 -0.014 0.283 0.530 -15.8 90.1 52.3
entire -0.002 -0.001 0.001 -0.008 0.340 0.596 -29.8 83.2 52.6
2000
GC
outcome 0.000 0.000 -0.000 -0.002 0.108 0.479 -1.7 94.7 99.6
treatment 0.001 0.000 -0.000 -0.003 0.122 0.524 -1.2 94.8 98.6
common 0.001 0.000 -0.000 -0.003 0.116 0.480 -0.9 94.7 99.1
entire 0.000 0.000 -0.000 -0.002 0.113 0.523 -1.8 94.5 99.4
IPTW
outcome 0.002 0.000 -0.001 -0.006 0.113 0.478 16.3 97.6 98.1
treatment 0.000 0.000 -0.000 -0.002 0.138 0.539 7.9 96.4 93.0
common 0.002 0.000 -0.001 -0.006 0.120 0.480 9.4 97.0 97.7
entire 0.000 0.000 -0.000 -0.002 0.131 0.537 13.9 97.4 93.6
TMLE
outcome 0.001 0.000 -0.000 -0.002 0.132 0.483 -5.9 93.3 97.5
treatment 0.000 0.000 0.000 -0.002 0.169 0.568 18.2 98.2 71.8
common -0.000 0.000 0.000 -0.000 0.142 0.486 -5.6 93.6 95.5
entire 0.001 0.000 -0.000 -0.004 0.158 0.565 23.5 98.6 75.3
FM
outcome 0.000 0.000 -0.000 -0.002 0.134 0.484 -12.0 91.6 97.7
treatment 0.001 0.000 -0.000 -0.005 0.203 0.548 -41.6 74.6 89.9
common 0.001 0.000 -0.000 -0.003 0.149 0.485 -20.5 88.5 96.7
entire 0.000 0.000 0.000 -0.002 0.162 0.543 -26.9 84.5 94.8
Table 1. Simulation results comparing the ATT estimation under the alternative hypothesis. * MSE in the presence of
an unmeasured confounder. Theoretical values: pi1 = 0.701,pi0 = 0.589,θ = 0.492.
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n method set mean bias logORpi0 pi1 ∆pi logOR MSE MSE* VEB coverage power
100
GC
outcome -0.001 -0.002 -0.001 -0.003 0.404 0.634 -7.3 93.2 24.7
treatment -0.002 -0.001 0.000 0.004 0.477 0.727 -9.5 92.4 19.9
common -0.001 -0.002 -0.001 -0.002 0.434 0.650 -6.6 93.5 22.1
entire -0.002 -0.001 0.001 0.003 0.450 0.714 -11.4 91.8 22.6
IPTW
outcome -0.003 -0.001 0.001 0.011 0.464 0.646 12.1 97.4 12.1
treatment -0.006 0.002 0.008 0.046 0.633 0.769 -7.6 93.8 16.7
common -0.002 -0.001 0.001 0.010 0.480 0.657 6.3 96.3 13.5
entire -0.006 0.003 0.009 0.053 0.647 0.773 -7.2 94.7 16.4
TMLE
outcome -0.001 -0.002 -0.000 0.003 0.438 0.642 -14.3 89.5 26.9
treatment -0.004 0.002 0.006 0.039 0.572 0.757 -24.9 84.3 27.5
common -0.001 -0.002 -0.001 0.002 0.469 0.657 -10.7 90.9 21.2
entire -0.005 0.003 0.007 0.043 0.544 0.748 -30.7 80.9 34.3
FM
outcome -0.005 0.002 0.006 0.039 0.549 0.710 -24.3 87.1 28.5
treatment -0.009 0.005 0.014 0.082 0.677 0.832 -37.7 78.0 35.1
common -0.005 0.001 0.006 0.038 0.563 0.713 -26.3 85.8 29.1
entire -0.007 0.006 0.014 0.082 0.674 0.830 -37.3 78.1 34.8
300
GC
outcome -0.000 -0.000 0.000 0.001 0.221 0.532 -1.9 94.5 59.8
treatment -0.000 -0.000 0.000 0.001 0.259 0.608 -2.8 94.3 47.4
common -0.000 -0.000 0.000 0.001 0.237 0.539 -1.2 94.8 53.5
entire -0.000 -0.000 0.000 0.001 0.241 0.600 -3.4 94.0 53.0
IPTW
outcome -0.001 -0.000 0.001 0.006 0.239 0.533 20.2 98.0 34.7
treatment -0.002 0.000 0.003 0.014 0.330 0.615 4.6 96.0 29.5
common -0.001 -0.000 0.001 0.006 0.252 0.541 13.3 97.4 36.5
entire -0.002 0.000 0.002 0.013 0.326 0.607 7.9 96.6 28.5
TMLE
outcome -0.000 -0.001 -0.000 0.000 0.233 0.532 -3.0 93.9 54.2
treatment -0.001 0.000 0.002 0.009 0.310 0.612 -10.4 90.6 40.2
common -0.001 -0.001 0.000 0.001 0.249 0.540 -1.5 94.6 48.1
entire -0.001 0.000 0.001 0.008 0.290 0.603 -13.2 89.6 46.1
FM
outcome -0.002 0.000 0.002 0.010 0.294 0.552 -20.2 88.7 51.6
treatment -0.003 0.003 0.006 0.032 0.389 0.652 -39.3 77.0 53.3
common -0.001 -0.000 0.001 0.008 0.315 0.588 -25.5 86.2 51.3
entire -0.003 0.003 0.006 0.032 0.377 0.644 -37.4 77.8 52.2
500
GC
outcome -0.000 0.000 0.001 0.003 0.168 0.501 -0.4 94.8 81.1
treatment -0.000 0.000 0.001 0.002 0.198 0.573 -1.0 94.8 69.0
common -0.000 0.000 0.000 0.002 0.183 0.505 -0.7 94.9 75.0
entire -0.000 0.000 0.001 0.004 0.183 0.569 -1.0 94.8 75.3
IPTW
outcome -0.001 0.000 0.001 0.005 0.180 0.501 22.2 98.3 58.5
treatment -0.001 0.001 0.001 0.007 0.248 0.573 8.1 96.5 42.3
common -0.001 0.000 0.001 0.005 0.193 0.505 13.8 97.3 58.6
entire -0.001 0.000 0.001 0.006 0.239 0.569 13.1 97.2 41.3
TMLE
outcome -0.000 0.000 0.000 0.002 0.177 0.501 -0.8 94.7 76.8
treatment -0.000 0.000 0.000 0.003 0.234 0.571 -5.9 92.7 56.1
common -0.000 0.000 0.000 0.002 0.190 0.505 -0.5 94.7 69.7
entire -0.000 0.000 0.000 0.003 0.218 0.566 -7.5 91.8 63.1
FM
outcome -0.001 0.000 0.001 0.005 0.219 0.518 -17.5 89.8 70.1
treatment -0.002 0.002 0.003 0.018 0.302 0.598 -39.8 76.2 65.5
common -0.001 -0.000 0.001 0.005 0.266 0.555 -31.8 82.3 66.4
entire -0.002 0.002 0.004 0.019 0.289 0.592 -37.1 78.3 66.2
2000
GC
outcome -0.000 -0.000 -0.000 -0.001 0.085 0.482 -0.6 94.6 100.0
treatment 0.000 -0.001 -0.001 -0.003 0.099 0.550 -0.6 94.7 99.8
common 0.000 -0.001 -0.001 -0.003 0.092 0.483 -0.8 94.7 99.9
entire -0.000 -0.000 -0.000 -0.001 0.091 0.550 -0.6 94.7 99.9
IPTW
outcome -0.000 -0.000 0.000 0.002 0.090 0.482 21.2 98.2 99.8
treatment 0.000 -0.001 -0.001 -0.002 0.122 0.547 9.3 96.7 95.1
common -0.000 -0.000 0.000 0.001 0.096 0.483 13.5 97.3 99.7
entire 0.000 -0.000 -0.001 -0.002 0.117 0.546 14.3 97.5 95.6
TMLE
outcome -0.000 -0.000 -0.000 -0.001 0.088 0.482 -0.6 94.8 100.0
treatment 0.000 -0.001 -0.001 -0.003 0.116 0.545 -2.2 94.4 98.7
common 0.000 -0.000 -0.001 -0.002 0.095 0.483 -0.3 94.8 99.9
entire 0.000 -0.000 -0.001 -0.002 0.108 0.544 -2.6 94.1 99.4
FM
outcome -0.000 -0.000 -0.000 0.000 0.129 0.497 -29.9 82.9 99.0
treatment -0.001 -0.000 0.000 0.003 0.169 0.569 -46.6 70.6 96.2
common 0.000 -0.000 -0.001 -0.001 0.205 0.534 -55.9 61.1 92.7
entire -0.000 -0.000 0.000 0.002 0.145 0.549 -37.7 77.9 98.2
Table 2. Simulation results comparing the ATE estimation under the alternative hypothesis. * MSE in the presence of
an unmeasured confounder. Theoretical values: pi1 = 0.557,pi0 = 0.441,θ = 0.466.
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application method set pˆi0 pˆi1 θˆ SE 95% CI
A -
Multiple
sclerosis
GC
outcome 20.3 28.2 0.432 0.189 [0.062, 0.802]
treatment* 20.3 28.3 0.436 0.195 [0.054, 0.819]
common* 20.3 28.3 0.436 0.195 [0.054, 0.819]
entire 20.3 28.2 0.431 0.191 [0.056, 0.806]
IPTW
outcome 21.2 28.8 0.406 0.195 [0.023, 0.789]
treatment* 20.3 28.2 0.433 0.191 [0.059, 0.808]
common* 20.3 28.2 0.433 0.191 [0.059, 0.808]
entire 21.3 28.9 0.406 0.196 [0.022, 0.791]
TMLE
outcome 21.2 28.8 0.407 0.195 [0.025, 0.790]
treatment* 20.3 28.2 0.433 0.190 [0.061, 0.806]
common* 20.3 28.2 0.433 0.190 [0.061, 0.806]
entire 21.1 28.9 0.410 0.196 [0.026, 0.794]
FM
outcome 19.1 29.0 0.549 0.189 [0.178, 0.921]
treatment* 19.9 30.6 0.575 0.187 [0.210, 0.941]
common* 19.9 30.6 0.575 0.187 [0.210, 0.941]
entire 21.1 31.9 0.561 0.183 [0.201, 0.920]
B - ICU
GC
outcome 66.3 81.1 0.778 0.294 [0.201, 1.354]
treatment 65.3 81.1 0.824 0.298 [0.240, 1.407]
common 65.0 81.1 0.836 0.289 [0.270, 1.402]
entire 66.5 81.1 0.769 0.295 [0.191, 1.347]
IPTW
outcome 31.0 81.1 0.656 0.356 [-0.042, 1.354]
treatment 68.2 81.1 0.693 0.355 [-0.002, 1.388]
common 67.4 81.1 0.729 0.353 [0.038, 1.421]
entire 69.2 81.1 0.645 0.362 [-0.064, 1.354]
TMLE
outcome 66.2 79.6 0.692 0.293 [0.118, 1.266]
treatment 65.4 80.2 0.758 0.288 [0.194, 1.322]
common 64.8 79.9 0.769 0.298 [0.185, 1.354]
entire 66.4 79.4 0.668 0.285 [0.109, 1.228]
FM
outcome 73.8 81.1 0.419 0.342 [-0.252, 1.090]
treatment 67.2 81.1 0.739 0.337 [0.078, 1.399]
common 65.1 81.1 0.831 0.336 [0.173, 1.490]
entire 66.2 81.1 0.782 0.336 [0.123, 1.442]
Table 4. Results of the two applications. * Treatment and common sets contain same variables. pi0: Percentage of event in
the Natalizumab (or control) group, pi1: Percentage of event in the Fingolimod (or Barbiturates) group, SE: standard error.
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